test

Colorectal Cancer

10
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer Refractory to Standard Therapies
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease/Condition: Colon
Principal Investigator: Sajid Khan
A Pilot Trial of KD018 with Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients with Locally Advanced Rectal Cancer
Disease/Condition: Rectum
Principal Investigator: Susan Higgins
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Disease/Condition: Anus | Colon
Principal Investigator: Neal Fischbach
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Principal Investigator: Melinda Irwin
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
Principal Investigator: Jennifer Choi
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Disease/Condition: Colon | Liver | Rectum
Principal Investigator: Howard Hochster
An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase Ib/II study of LGX818 and Cetuximab or LGX818, BYL719 and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster